Coupling of Fcγ receptor i to Fcγ receptor IIB by src kinase mediates c-reactive protein impairment of endothelial function

Circulation Research

Volumn 109, Issue 10, 2011, Pages 1132-1140

  Sundgren, Nathan C ^a   Zhu, Weifei ^a   Yuhanna, Ivan S ^a   Chambliss, Ken L ^a   Ahmed, Mohamed ^a   Tanigaki, Keiji ^a   Umetani, Michihisa ^a   Mineo, Chieko ^a   Shaul, Philip W ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

C reactive protein; endothelial nitric oxide synthase; Fc receptor

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FC RECEPTOR I; FC RECEPTOR IIB; IMMUNOGLOBULIN G; IMMUNOGLOBULIN RECEPTOR; INOSITOL 5' PHOSPHATASE 1; PHOSPHATASE; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CAROTID ARTERY; CONTROLLED STUDY; CROSS COUPLING REACTION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVATION; IMMUNOBLOTTING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGENY; REENDOTHELIALIZATION; VASCULARIZATION;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; C-REACTIVE PROTEIN; CAROTID ARTERY INJURIES; CATTLE; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; ENZYME ACTIVATION; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; RABBITS; RECEPTORS, IGG; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TIME FACTORS; TRANSFECTION;

EID: 80255123405     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.111.254573     Document Type: Article

References (37)

1. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397. (Pubitemid 38419992)
2. Genest J. C-reactive protein: risk factor, biomarker and/or therapeutic target? Can J Cardiol. 2010;26 Suppl A:41A-44A.
3. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347: 1557-1565. (Pubitemid 35315836)
4. Mineo C, Gormley AK, Yuhanna IS, Osborne-Lawrence S, Gibson LL, Hahner L, Shohet RV, Black S, Salmon JE, Samols D, Karp DR, Thomas GD, Shaul PW. FcgammaRIIB mediates C-reactive protein inhibition of endothelial NO synthase. Circ Res. 2005;97:1124-1131.
5. Schwartz R, Osborne-Lawrence S, Hahner L, Gibson LL, Gormley AK, Vongpatanasin W, Zhu W, Word RA, Seetharam D, Black S, Samols D, Mineo C, Shaul PW. C-reactive protein downregulates endothelial NO synthase and attenuates reendothelialization in vivo in mice. Circ Res. 2007;100:1452-1459. (Pubitemid 46834757)
6. Vongpatanasin W, Thomas GD, Schwartz R, Cassis LA, Osborne-Lawrence S, Hahner L, Gibson LL, Black S, Samols D, Shaul PW. C-reactive protein causes downregulation of vascular angiotensin subtype 2 receptors and systolic hypertension in mice. Circulation. 2007;115: 1020-1028. (Pubitemid 46328296)
7. Mold C, Baca R, Du Clos TW. Serum amyloid P component and C-reactive protein opsonize apoptotic cells for phagocytosis through Fcgamma receptors. J Autoimmun. 2002;19:147-154. (Pubitemid 35341864)
8. Ravetch JV. A full complement of receptors in immune complex diseases. J Clin Invest. 2002;110:1759-1761. (Pubitemid 36076480)
9. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol. 2001;19: 275-290. (Pubitemid 32368037)
10. Tanigaki K, Mineo C, Yuhanna IS, Chambliss KL, Quon MJ, Bonvini E, Shaul PW. C-reactive protein inhibits insulin activation of endothelial nitric oxide synthase via the immunoreceptor tyrosine-based inhibition motif of FcgammaRIIB and SHIP-1. Circ Res. 2009;104:1275-1282.
11. Ravetch JV, Lanier LL. Immune inhibitory receptors. Science. 2000;290: 84-89.
12. Devaraj S, Du Clos TW, Jialal I. Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arterioscler Thromb Vasc Biol. 2005;25:1359-1363. (Pubitemid 40923352)
13. Kobayashi M, Inoue K, Warabi E, Minami T, Kodama T. A simple method of isolating mouse aortic endothelial cells. J Atheroscler Thromb. 2005;12:138-142.
14. Seetharam D, Mineo C, Gormley AK, Gibson LL, Vongpatanasin W, Chambliss KL, Hahner LD, Cummings ML, Kitchens RL, Marcel YL, Rader DJ, Shaul PW. High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ Res. 2006;98:63-72. (Pubitemid 43970204)
15. Black S, Agrawal A, Samols D. The phosphocholine and the polycationbinding sites on rabbit C-reactive protein are structurally and functionally distinct. Mol Immunol. 2003;39:1045-1054. (Pubitemid 36577124)
16. Mineo C, Yuhanna IS, Quon MJ, Shaul PW. High density lipoproteininduced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem. 2003;278:9142-9149. (Pubitemid 36800395)
17. Blake GJ, Rifai N, Buring JE, Ridker PM. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation. 2003;108: 2993-2999. (Pubitemid 37553568)
18. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
19. Lu J, Marnell LL, Marjon KD, Mold C, Du Clos TW, Sun PD. Structural recognition and functional activation of FcgammaR by innate pentraxins. Nature. 2008;456:989-992.
20. Bautista LE, Lopez-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens. 2001;19:857-861. (Pubitemid 32436948)
21. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation. 2000; 102:1000-1006. (Pubitemid 30657516)
22. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension. 2004;44:6-11. (Pubitemid 38823477)
23. Black S, Kushner I, Samols D. C-reactive Protein. J Biol Chem. 2004; 279:48487-48490. (Pubitemid 39625721)
24. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev. 2007;28:463-491. (Pubitemid 47236334)
25. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8:34-47.
26. Turner M, Schweighoffer E, Colucci F, Di Santo JP, Tybulewicz VL. Tyrosine kinase SYK: essential functions for immunoreceptor signalling. Immunol Today. 2000;21:148-154. (Pubitemid 30122705)
27. Haynes MP, Li L, Sinha D, Russell KS, Hisamoto K, Baron R, Collinge M, Sessa WC, Bender JR. Src kinase mediates phosphatidylinositol 3-kinase/Akt-dependent rapid endothelial nitric-oxide synthase activation by estrogen. J Biol Chem. 2003;278:2118-2123. (Pubitemid 36801275)
28. Jin ZG, Ueba H, Tanimoto T, Lungu AO, Frame MD, Berk BC. Ligandindependent activation of vascular endothelial growth factor receptor 2 by fluid shear stress regulates activation of endothelial nitric oxide synthase. Circ Res. 2003;93:354-363. (Pubitemid 37048248)
29. Bradshaw JM. The Src, Syk, and Tec family kinases: distinct types of molecular switches. Cell Signal. 2010;22:1175-1184.
30. Zhu W, Saddar S, Seetharam D, Chambliss KL, Longoria C, Silver DL, Yuhanna IS, Shaul PW, Mineo C. The scavenger receptor class B type I adaptor protein PDZK1 maintains endothelial monolayer integrity. Circ Res. 2008;102:480-487. (Pubitemid 351651102)
31. Escarcega RO, Garcia-Carrasco M, Fuentes-Alexandro S, Jara LJ, Rojas-Rodriguez J, Escobar-Linares LE, Cervera R. Insulin resistance, chronic inflammatory state and the link with systemic lupus erythematosusrelated coronary disease. Autoimmun Rev. 2006;6:48-53. (Pubitemid 44781092)
32. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum. 2005;35:8-17. (Pubitemid 41111466)
33. Smith KG, Clatworthy MR. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol. 2010; 10:328-343.
34. Dhodapkar KM, Kaufman JL, Ehlers M, Banerjee DK, Bonvini E, Koenig S, Steinman RM, Ravetch JV, Dhodapkar MV. Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc Natl Acad Sci USA. 2005;102:2910-2915. (Pubitemid 40299890)
35. Teoh H, Quan A, Lovren F, Wang G, Tirgari S, Szmitko PE, Szalai AJ, Ward ME, Verma S. Impaired endothelial function in C-reactive protein overexpressing mice. Atherosclerosis. 2008;201:318-325.
36. Xing D, Hage FG, Chen YF, McCrory MA, Feng W, Skibinski GA, Majid-Hassan E, Oparil S, Szalai AJ. Exaggerated neointima formation in human C-reactive protein transgenic mice is IgG Fc receptor type I (Fc gamma RI)-dependent. Am J Pathol. 2008;172: 22-30. (Pubitemid 351186364)
37. Bournazos S, Woof JM, Hart SP, Dransfield I. Functional and clinical consequences of Fc receptor polymorphic and copy number variants. Clin Exp Immunol. 2009;157:244-254.